S. 2876 (96th): Contraceptive Labeling and Advertising Act

Introduced:
Jun 25, 1980 (96th Congress, 1979–1980)
Status:
Died (Referred to Committee)
Sponsor
Jacob Javits
Senator from New York
Party
Republican
 
Status

This bill was introduced on June 25, 1980, in a previous session of Congress, but was not enacted.

Progress
Introduced Jun 25, 1980
Referred to Committee Jun 25, 1980
 
Full Title

A bill to amend the Federal Food, Drug and Cosmetic Act to require that the label and advertising for contraceptive drugs and devices state the effectiveness of the drugs and devices in preventing conception in humans, and for other purposes.

Summary

No summaries available.

Cosponsors
1 cosponsors (1D) (show)
Committees

Senate Health, Education, Labor, and Pensions

The committee chair determines whether a bill will move past the committee stage.

 
Primary Source

THOMAS.gov (The Library of Congress)

GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here. Data comes via the congress project.

Widget

Get a bill status widget for your website »

Citation

Click a format for a citation suggestion:

Notes

S. stands for Senate bill.

A bill must be passed by both the House and Senate in identical form and then be signed by the president to become law.

The bill’s title was written by its sponsor.

GovTrack’s Bill Summary

We don’t have a summary available yet.

Library of Congress Summary

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress.


6/25/1980--Introduced.
Contraceptive Labeling and Advertising Act - Amends the Federal Food, Drug, and Cosmetic Act to require that the label for contraceptive drugs and devices state:
(1) the range of effectiveness of such drugs and devices in preventing contraception in humans;
(2) the directions for use; and
(3) that professional advice should be sought to determine the most appropriate form of contraception.
Requires information labeling to accompany such drug or device which summarizes the benefits and risks and states adequate directions for use and storage.
Requires advertisements and other printed descriptive matter issued with respect to such drug or device to contain information respecting the range of effectiveness based upon clinical and use testing results.

House Republican Conference Summary

The summary below was written by the House Republican Conference, which is the caucus of Republicans in the House of Representatives.


No summary available.

House Democratic Caucus Summary

The House Democratic Caucus does not provide summaries of bills.

So, yes, we display the House Republican Conference’s summaries when available even if we do not have a Democratic summary available. That’s because we feel it is better to give you as much information as possible, even if we cannot provide every viewpoint.

We’ll be looking for a source of summaries from the other side in the meanwhile.

Use the comment space below for discussion of the merits of S. 2876 (96th) with other GovTrack users.
Your comments are not read by Congressional staff.

comments powered by Disqus